N-Acetylcarnosine Can-C™ Eye Drops with 1% N-Acetyl-CarnosineProduct Questions? 1-800.861.4936
Initial results in only 3 months time! Optimal Results within 6 - 12 months!
FAQ and Instructions
Over the last 10 years this, soothing, anti-oxidant, eye drop, has generated thousands of reports of safe and effective Cataract Reversal in both humans and in animals . "We see the demand for this breakthrough product snowballing as consumers around the globe become aware of a viable non-surgical option to cataract surgery.." Dr. Mark Babizhayev MA PhD Dr. Mark Babizhayev expresses important message to consumers - Read it Here
Can-C™ Eye Drops applied for 6-months, (twice daily into the eye), in patients suffering from cataract, generated the following results:
- 90% had an improvement in visual acuity.
- 88.9% had an improvement of glare sensitivity.
- 41.5% had an improvement of the transmissivity of the lens.
Approved by Innovative Vision Products, Can-C™ is manufactured by a licensed manufacturer located in Great Britain in a GMP certified, pharmaceutical facility which meets ISO 9001:2000 and ISO 13485:2003 standards for the design/formulation and manufacture of sterile contact lens solution and pharmaceutical solutions. Our Refund Policy: Simply return any unused portion along with your comments. We will promptly provide a refund for any unopened vials now questions asked, (Less shipping and a 15% restocking fee)
Human Clinical TrialsIn a Russian clinical trial Carnosine eye-drops were used to treat 96 patients aged 60 and above. All the patients had senile cataract in various degrees of maturity. The duration of the disease in these patients ranged between 2 and 21 years. The patients instilled 1 or 2 drops into each eye 3 or 4 times a day, for a period of 3 to 6 months. The results showed that there was a pronounced effect on senile cataract, the rate was 100% (i. e. all patients experienced an improvement). For the more mature senile cataract the effective rate was still an extremely impressive 80%. Importantly, it was also noted that there were no side effects in any of the cases.
A second clinical study was designed to document and quantify the changes in lens clarity over a 6 to 24 month period. The averageage of the participants was 65 and all suffered from senile cataract of a minimal to an advanced opacification. The patients received either a 1% solution of N-acetylcarnosine eye-drops or a placebo as 2-drops twice a day into each eye. The results at 6 months were impressive; 88.9% of all eyes treated with N-acetylcarnosine had an improvement of glare sensitivity. Furthermore, 90% of the eyes treated with N-acetylcarnosine showed an improvement in visual acuity. In contrast, there was little change in the eye quality of the placebo group at 6 months and the placebo group also experienced a gradual deterioration at 12 to 24 months.
Another study evaluated patients who had various degrees of eyesight impairment but who did not have the symptoms of cataract. After a course of treatment ranging from 2 to 6 months the conclusion was that the eye-drops alleviated eye tiredness and continued to improve eyesight (i. e. there was more clear vision). This is an indicator that the eye-drops have a value both for preventative purposes as well as medical applications. Clinical Publications
This unique "IVP" N-acetylcarnosine (Can-C™) formula with synergistic lubricants shows beneficial results for the following eye-disorders
- Contact lens disorders.
- Corneal disorders.
- Chronic eyestrain.
- Computer vision syndrome.
- Ocular inflammation.
- Blurred vision.
- Dry eye syndrome.
- Retinal disease
- Vitreous opacities and lesions.
Not only do the lubricants in Can-C N-acetyl-carnosine eye-drops help to make wearing contact lenses more comfortable, but Can-C is also shown to soothe and reduce the build up of lactic acid in the eye, thus enabling the lens to be left safely in the eye for longer. Manufactured to cGMP pharmaceutical standards, Can-C™ has a wealth of anti-oxidant properties which can improve the overall function of the aging eye.